Design considerations for AIDS trials. by Byar, D, Schoenfeld, D, Green, S, Amato, D, Davis, R, De Gruttola, V, Finkelstein, D, Gatsonis, C, Gelber, R, Lagakos, S

Design of vaccine efficacy trials during public health emergencies by Dean, N, Gsell, P-S, Brookmeyer, R, De Gruttola, V, Donnelly, CA, Halloran, ME, Jasseh, M, Nason, M, Riveros, X, Watson, CH, Henao-Restrepo, A-M, Longini, IM

A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats by Longini, IM, Yang, Y, Fleming, TR, Muñoz-Fontela, C, Wang, R, Ellenberg, SS, Qian, G, Halloran, ME, Nason, M, De Gruttola, V, Mulangu, S, Huang, Y, Donnelly, CA, Henao Restrepo, A-M

Simulations for designing and interpreting intervention trials in infectious diseases by Halloran, ME, Auranen, K, Baird, S, Brookmeyer, R, Cooper, BS, DeGruttola, V, Hughes, JP, Lessler, J, Lofgren, ET, Longini, IM, Onnela, J-P, Özler, B, Vespignani, A, Vynnycky, E, Lipsitch, M

Creating a framework for conducting randomized clinical trials during disease outbreaks by Dean, NE, Gsell, P-S, Brookmeyer, R, Crawford, FW, Donnelly, CA, Ellenberg, SS, Fleming, TR, Halloran, ME, Horby, P, Jaki, T, Krause, PR, Longini, IM, Mulangu, S, Muyembe-Tamfum, J-J, Nason, MC, Smith, PG, Wang, R, Henao-Restrepo, AM, De Gruttola, V

Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group. by Abrams, D, Allan, D, Antunes, F, Breckenridge, A, Bruun, J, Cameron, W, Carbon, C, Chalmers, I, Chang, H, Chodakewitz, J, Clendenin, N, Clumeck, N, Collier, A, Collins, G, Cooper, E, Cooper, D, Danner, S, D'Aquila, R, DeGruttola, V, DeMasi, R, Dee, L, Deyton, L, Dixon, D, Farthing, C, Feinberg, J